SEC Form 4 · accession 0001209191-17-014875
Cyclacel Pharmaceuticals, Inc. · CYCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Kevin C Tang
10% Owner
TANG CAPITAL PARTNERS LP
10% Owner
TANG CAPITAL MANAGEMENT LLC
10% Owner
Period of report
Feb 23, 2017
Accepted (ET)
Feb 27, 2017 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001130166
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 23, 2017 | P | 134,200 | $4.3374 | A | 559,900 | I | By LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.